Gotham Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Gotham Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,708	Closed	-$466K	–	1461
2023 Q3	$466K	Buy	+10,708	New	+$382K	0.01%	980
2022 Q1	–	Sell	-1,581	Closed	-$232K	–	1271
2021 Q4	$232K	Buy	1,581 +126	+9%	+$19.6K	0.01%	1035
2021 Q3	$257K	Sell	1,455 -452	-24%	-$72.7K	0.01%	891
2021 Q2	$308K	Buy	1,907 +393	+26%	+$63.1K	0.01%	837
2021 Q1	$259K	Hold	1,514	–	–	0.01%	882
2020 Q4	$333K	Hold	1,514	–	–	0.01%	805
2020 Q3	$251K	Buy	+1,514	New	+$207K	0.01%	878
2020 Q1	–	Sell	-1,928	Closed	-$248K	–	1242
2019 Q4	$248K	Buy	+1,928	New	+$186K	﹤0.01%	993
2019 Q3	–	Sell	-3,408	Closed	-$351K	–	1249
2019 Q2	$351K	Sell	3,408 -458	-12%	-$35.7K	0.01%	900
2019 Q1	$283K	Buy	+3,866	New	+$263K	﹤0.01%	1009

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Gotham Asset Management's MRTX Position: Q4 2023 in Review

Gotham Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 10,708 shares — an estimated $466K sold.

Gotham Asset Management first reported a position in MRTX in Q1 2019 and held it in 10 quarters. The position peaked at $466K in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Gotham Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Gotham Asset Management sold 10,708 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $466K.
Gotham Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 10 quarters.
Gotham Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $466K in Q3 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Gotham Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.